| Item Type | Name |
|
Concept
|
Leukemia, Myeloid
|
|
Concept
|
Leukemia, Myeloid, Acute
|
|
Concept
|
Leukemia, Myeloid, Chronic-Phase
|
|
Concept
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
|
Academic Article
|
Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML-2 cell line.
|
|
Academic Article
|
Therapy-related myeloid leukemia.
|
|
Academic Article
|
Bronchiolitis obliterans organizing pneumonia as a complication of allogeneic bone marrow transplantation.
|
|
Academic Article
|
Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites.
|
|
Academic Article
|
Developmental analysis and subcellular localization of the murine homologue of ELL.
|
|
Academic Article
|
Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia.
|
|
Academic Article
|
Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice.
|
|
Academic Article
|
ELL and EAF1 are Cajal body components that are disrupted in MLL-ELL leukemia.
|
|
Academic Article
|
ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties.
|
|
Academic Article
|
Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16).
|
|
Academic Article
|
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
|
|
Academic Article
|
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations.
|
|
Academic Article
|
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
|
|
Academic Article
|
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?
|
|
Academic Article
|
Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia.
|
|
Academic Article
|
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.
|
|
Academic Article
|
Heterogeneity of breakpoints of 11q23 rearrangements in hematologic malignancies identified with fluorescence in situ hybridization.
|
|
Academic Article
|
Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias.
|
|
Academic Article
|
Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia.
|
|
Academic Article
|
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
|
|
Academic Article
|
Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations.
|
|
Academic Article
|
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
|
|
Academic Article
|
Paradoxical Effects of MLL Paralogs in MLL-Rearranged Leukemia.
|
|
Academic Article
|
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
|
|
Academic Article
|
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
|
|
Academic Article
|
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.
|
|
Academic Article
|
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
|
|
Academic Article
|
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
|
|
Academic Article
|
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
|
|
Academic Article
|
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
|
|
Academic Article
|
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.
|
|
Academic Article
|
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
|
|
Academic Article
|
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
|